RE: Size trade23 Jul 2025 10:22
True. SGC alone is slated to achieve peak sales of 250m
Put that on a modest 4x multiple and avacta is already a 1bn company. Note also the almost certainty this happens given 91% disease control rate, at least doubling of the progression free survival, the better quality of life for patients and the fact there is no standard of care. Also note these patience are all heavily pre treated. How does the drug respond to patience who are otherwise healthy.
Avacta is chronically and grossly undervalued but that is now being corrected. 30p protects the downside and the upside is almost incalculable. It's beyond comprehension which is what most people don't get when they see a phase 1 bio valued at over £100m already
Oh well, sucks to be them. I got 10k in here while most were c r a pp in their pants